Anastrozole vs Meldonium
FDA Approved vs Moderate Research
monitor Mechanism-based · 47% Both Anastrozole and Meldonium negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle.
Molecular Data
Anastrozole Meldonium
Weight 293.37 Da 146.19 Da
Half-life ~40-50 hours ~4-6 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) Hydrazinium derivative (C6H14N2O2)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Meldonium
01 Cardioprotective effects through metabolic optimization under ischemic conditions
02 Shifts cardiac energy metabolism from fatty acid oxidation to more oxygen-efficient glucose oxidation
03 Reduces accumulation of toxic fatty acid intermediates (long-chain acylcarnitines) in heart tissue
04 Promotes nitric oxide synthesis and endothelial function via GBB accumulation
05 May improve exercise capacity and reduce recovery time through enhanced glucose utilization
06 Used as adjunctive cardiac protection during anabolic steroid cycles to mitigate androgen-induced cardiotoxicity
07 Well-established safety profile in Eastern European clinical use spanning over 30 years
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Meldonium
Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)
Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Known hypersensitivity to meldonium or any excipients
Pregnancy or breastfeeding (insufficient safety data)
Individuals under 18 years of age
Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)
Increased intracranial pressure (listed as a contraindication in some regional prescribing information)
Research Evidence
Anastrozole Meldonium
Status FDA Approved Moderate Research
References 5 studies 4 studies
Latest — 2016
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.